Recent Updates in the Management of Anaphylaxis: The Role of the Pediatrician Authors: Jonathan M Spergel, Anna Nowak-Wegrzyn, Joel Brooks, Suzanne Kochis Published: 2026 ABSTRACT AbstractAnaphylaxis is a rapid-onset, potentially life-threatening systemic allergic reaction that remains a significant clinical concern in pediatric practice. Food allergies are the most common trigger in children, and a substantial proportion of affected patients experience severe reactions. This review provides a practical, evidence-based framework for the diagnosis and management of IgE-mediated allergy in the pediatric setting, emphasizing recognition, treatment, and preparedness. Anaphylaxis is a clinical diagnosis based on established criteria, with age-specific presentations that may complicate recognition, particularly in infants and young children. Epinephrine is the cornerstone of treatment and the only therapy capable of reversing life-threatening respiratory and cardiovascular manifestations. Early epinephrine administration improves outcomes, yet real-world use remains suboptimal due to barriers such as needle aversion, device complexity, and access challenges. Pediatricians play a critical role in identifying at-risk patients, prescribing epinephrine, and reinforcing preparedness through education and individualized action plans across care settings. Integrating evolving therapeutic options with established best practices may help to address persistent gaps in care and improve outcomes for children at risk of anaphylaxis.Keywords: anaphylaxis, food allergy, epinephrine, IgE-mediated allergy Anaphylaxis is a rapid-onset, systemic allergic reaction that can be life threatening without prompt recognition and treatment. Although the precise incidence in pediatric populations is unknown, population-based estimates suggest that 1.6%-5.1% of people experience anaphylaxis at some point in their lifetime.1,2 Foods represent the most common identifiable allergen in children, affecting an estimated 7.6% of children in the US, followed by insect venom and medications.3, 4, 5, 6, 7 Among pediatric patients with a food allergy, the burden of anaphylaxis is substantial: an estimated 42.3% have experienced at least 1 severe reaction (defined as the presence of multiple symptoms involving at least 2 organ systems), and nearly 1 in 5 have had a food allergy-related emergency department visit in the last year.7 Together, these data highlight anaphylaxis as a critical pediatric health concern and underscore the need for clinicians to recognize anaphylaxis promptly, counsel families about emergency preparedness, and ensure timely access to effective treatment with epinephrine. The majority of anaphylaxis is mediated by IgE-dependent immune mechanisms. The process begins with sensitization, in which exposure to an allergen leads to the activation of a type 2 helper T-cell immune response.8,9 Antigen-presenting cells stimulate naive CD4+ T cells to differentiate into type 2 helper T cells that secrete cytokines such as IL-4 and IL-13, promoting class switching in B cells and the production of allergen-specific IgE.10 These IgE antibodies bind with high affinity to FcεRI receptors on mast cells and basophils, effectively priming these cells for subsequent reactions. Upon re-exposure to the allergen, crosslinking of receptor-bound IgE triggers rapid cellular degranulation and the release of preformed mediators, including histamine and mast cell proteases such as tryptase. Within minutes, newly synthesized lipid mediators, including prostaglandins and leukotrienes, further amplify inflammation. The combined effects of these mediators can ultimately increase vascular permeability and vasodilation, potentially leading to tissue edema, hypotension, and tachycardia. Smooth muscle contraction contributes to bronchospasm and gastrointestinal symptoms, all of which are the hallmark features of anaphylaxis.8, 9, 10 For pediatric patients at risk of anaphylaxis, the established standard of care has remained consistent for decades and centers on reaction prevention, preparedness, and rapid response.2,11, 12, 13, 14 Core components include confirmation and avoidance of known triggers, counseling for patients and families on the early recognition of symptoms, and epinephrine carriage and use as first-line therapy in case of anaphylaxis after accidental exposure. Guidelines emphasize that prompt administration of epinephrine is the cornerstone of anaphylaxis treatment, with strong evidence demonstrating that early use is both safe and effective.15 Contemporary guidelines continue to stress that epinephrine use should not be delayed, and adjunctive therapies such as antihistamines should be reserved for the relief of lingering cutaneous symptoms after epinephrine administration.2,11, 12, 13, 14 Although the fundamentals of anaphylaxis management remain unchanged, the surrounding landscape of prevention, immunomodulatory therapy, and emergency preparedness continues to evolve. Preventive strategies now emphasize early introduction of potentially allergenic foods during infancy at 4-6 months of age. This approach is supported by recent population-based data demonstrating decreases in peanut allergy and overall IgE-mediated food allergy in the period following US early introduction guideline updates.16 In parallel, therapeutic options aimed at modifying allergic risk have expanded. A US Food and Drug Administration (FDA)-approved peanut oral immunotherapy product (peanut [Arachis hypogaea] allergen powder-dnfp [Palforzia]) can increase reaction thresholds for some children with peanut allergy, and anti-IgE monoclonal antibody therapy (omalizumab [Xolair]) has been approved to reduce the likelihood of allergic reactions following accidental exposure to one or more foods.17,18 Although these strategies may lessen the risk or severity of anaphylaxis from low-dose exposures, they do not eliminate the need for immediate access to epinephrine for the treatment of anaphylaxis. Within this context, the recent approval of a needle-free intranasal epinephrine formulation (epinephrine nasal spray [neffy]) represents an important development in emergency preparedness, offering an alternative epinephrine delivery option that may reduce barriers related to needle aversion or technical challenges associated with injection and delayed administration in pediatric settings.19,20 A sublingual film formulation of epinephrine (Anaphylm) is also under development and is currently being reviewed by the FDA, potentially providing another needle-free delivery option in the future.21 Persistent shortages in the allergy workforce, particularly affecting children insured through Medicaid or living in underserved areas, mean that many children rely primarily on their pediatrician for ongoing allergy-related care.20,22,23 In this context, pediatricians play a critical role in identifying children at risk for anaphylaxis, providing evidence-based counseling on food allergy prevention, and recognizing those who may benefit from referral to an allergy specialist. Pediatricians are also central to emergency preparedness through timely epinephrine prescribing, symptom recognition education, and the development and reinforcement of individualized anaphylaxis action plans across home, school, and community environments. Accordingly, this review aimed to provide pediatricians with a practical, evidence-based framework for anaphylaxis recognition and reaction management, with an emphasis on the changing epinephrine administration landscape. The information and recommendations included in this article are based on the 2023 guidelines from the Allergy Immunology Joint Task Force on Practice Parameters (JTFPP) and a nonsystematic review of the published literature, as well as the expert opinions of the authors. Comprehensive Anaphylaxis Management Effective anaphylaxis management in pediatric practice requires timely recognition, decisive treatment, and proactive preparedness across care settings. Anaphylaxis can present heterogeneously and progress rapidly, particularly in infants and young children. Pediatricians must be familiar with established diagnostic criteria, age-specific clinical manifestations, and evidence-based response strategies. Importantly, early recognition and prompt administration of epinephrine remain the most critical determinants of outcomes, underscoring the need for clear counseling and practical training for families and caregivers. Beyond acute treatment, comprehensive anaphylaxis care also encompasses anticipatory guidance, risk stratification, and structured planning. Pediatricians play a central role in identifying children who warrant epinephrine prescriptions, reinforcing correct use and storage, and ensuring that individualized anaphylaxis action plans are in place and shared across home, school, and community environments. The following sections review key elements of anaphylaxis recognition, reaction management, and action planning in pediatric patients, with an emphasis on practical considerations relevant to the primary care setting. Recognizing Anaphylaxis Although multiple diagnostic frameworks have been proposed over the past 2 decades, the most widely used criteria in clinical practice are those established by the National Institute of Allergy and Infectious Disease in 2006 and updated by the World Allergy Organization (WAO) in 2020 (Table I).13,24 Both sets of criteria are based on clinical features only and emphasize a shared core concept: anaphylaxis is a serious, systemic allergic reaction with acute onset that may result in life-threatening respiratory and/or circulatory compromise. The National Institute of Allergy and Infectious Disease criteria define 3 clinical scenarios in which anaphylaxis is highly likely, including sudden mucocutaneous involvement accompanied by respiratory or cardiovascular symptoms, rapid involvement of 2 or more organ systems after exposure to a likely allergen, or hypotension after exposure to a known allergen.24 The WAO criteria streamline this approach, requiring the fulfillment of 1 of 2 conditions—either acute onset of mucocutaneous symptoms with respiratory, cardiovascular, or severe gastrointestinal involvement, or sudden bronchospasm after exposure to a highly probable allergen.13 Importantly, neither framework requires the identification of a specific trigger in all cases, reinforcing the need for clinicians to prioritize clinical features over allergen certainty when making treatment decisions. Although the 2023 Allergy Immunology JTFPP update of anaphylaxis guidelines reference both criteria, the authors note that the WAO criteria need more validation.2 Table IClinical criteria for the diagnosis of anaphylaxis in pediatric populations13,24NIAID (2006)WAO (2020)Anaphylaxis considered “highly likely” when…One of 3 criteria are fulfilledOne of 2 criteria are fulfilledCriteria1. Acute onset of symptoms within minutes to several hours involving the skin and/or mucosal tissue plus at least one of the following:•Respiratory compromise•Hypotension or signs/symptoms of end-organ dysfunction2. Onset of 2 or more of the following occurring within minutes to several hours after exposure to a likely allergen:•Skin or mucosal tissue involvement•Respiratory compromise•Hypotension or associated symptoms•Persistent GI symptoms3. Onset of hypotension within minutes to several hours after exposure to a known allergen, defined as low age-specific systolic BP or >30% decrease in systolic BP from patient baseline1. Acute onset of symptoms within minutes to several hours involving the skin and/or mucosal tissue plus at least one of the following:•Respiratory compromise•Hypotension or signs/symptoms of end-organ dysfunction•Severe GI symptoms, especially after exposure to nonfood allergens2. Onset of hypotension, bronchospasm, or laryngeal involvement within minutes to hours after exposure to a known or highly probable allergen (even in the absence of cutaneous symptoms)BP, blood pressure; GI, gastrointestinal; NIAID, National Institute of Allergy and Infectious Disease. Clinical criteria for the diagnosis of anaphylaxis in pediatric populations13,24 •Respiratory compromise Respiratory compromise •Hypotension or signs/symptoms of end-organ dysfunction Hypotension or signs/symptoms of end-organ dysfunction •Skin or mucosal tissue involvement Skin or mucosal tissue involvement •Respiratory compromise Respiratory compromise •Hypotension or associated symptoms Hypotension or associated symptoms •Persistent GI symptoms Persistent GI symptoms •Respiratory compromise Respiratory compromise •Hypotension or signs/symptoms of end-organ dysfunction Hypotension or signs/symptoms of end-organ dysfunction •Severe GI symptoms, especially after exposure to nonfood allergens Severe GI symptoms, especially after exposure to nonfood allergens BP, blood pressure; GI, gastrointestinal; NIAID, National Institute of Allergy and Infectious Disease. Clinically, anaphylaxis most often presents as a systemic reaction involving multiple organ systems, including the skin and mucosa, respiratory tract, cardiovascular system, and gastrointestinal tract, although single-organ presentations may occur and should not exclude the diagnosis.13,24,25 Cutaneous findings, particularly urticaria and angioedema of the face, lips, tongue, or larynx, are among the most common and recognizable features, but their absence does not rule out anaphylaxis. Respiratory symptoms, such as wheezing, stridor, or dyspnea, and cardiovascular signs, including hypotension, syncope, or collapse, signal severe disease and require immediate action. In pediatric patients, especially infants and young children, anaphylaxis may also manifest through less specific signs, such as sudden behavioral changes, persistent and/or hoarse crying, irritability, or lethargy. Older children and adolescents may report anxiety, apprehension, or a sense of impending doom.26,27 Furthermore, infants and toddlers are more likely to present with cutaneous and gastrointestinal symptoms and less likely to present with respiratory changes than older children and adults.28 Awareness of these age-related differences in presentation is critical; reliance on classic adult symptom descriptions may delay recognition and treatment in younger patients. Table II outlines the ways in which anaphylaxis may manifest in infants and children using terms that are familiar to families. Table IICaregiver-friendly signs and symptoms of anaphylaxis in pediatric patients, by age28, 29, 30, 31, 32, 33, 34, 35Organ systemSigns and symptoms that are recognizable by caregivers and/or Describable by patientsInfants and younger childrenOlder children and adolescentsAll agesMucocutaneous•Hives•Tongue thrusting•Tongue pulling•Repetitive licking of the lips, hands, or objects•Ear pulling or scratching•Eye rubbing•Throat itching•Tongue swelling•Hives•Swelling•Skin flushingRespiratory•Whistling or high-pitched sound while breathing•Tugging at chest or neck•Barky, croup-like, or hoarse cough•Hoarse crying•Cough•Throat tightness•Wheezing•Hoarse voice•Noisy breathing, especially on inhalationCardiovascular•Wobbly, floppy, or limp appearance•Lace-like or mottled skin appearance•Blue or gray skin near the mouth or on the hands or feet•Dizziness or lightheadedness•Confusion•Subdued or less active•Sleepiness and difficulty waking•Behavioral changes•Loss of consciousnessGastrointestinal•Spitting up•Back arching•Inconsolable crying•Abdominal pain•Nausea•Diarrhea•Vomiting Caregiver-friendly signs and symptoms of anaphylaxis in pediatric patients, by age28, 29, 30, 31, 32, 33, 34, 35 •Hives Hives •Tongue thrusting Tongue thrusting •Tongue pulling Tongue pulling •Repetitive licking of the lips, hands, or objects Repetitive licking of the lips, hands, or objects •Ear pulling or scratching Ear pulling or scratching •Eye rubbing Eye rubbing •Throat itching Throat itching •Tongue swelling Tongue swelling •Hives Hives •Swelling Swelling •Skin flushing Skin flushing •Whistling or high-pitched sound while breathing Whistling or high-pitched sound while breathing •Tugging at chest or neck Tugging at chest or neck •Barky, croup-like, or hoarse cough Barky, croup-like, or hoarse cough •Hoarse crying Hoarse crying •Cough Cough •Throat tightness Throat tightness •Wheezing Wheezing •Hoarse voice Hoarse voice •Noisy breathing, especially on inhalation Noisy breathing, especially on inhalation •Wobbly, floppy, or limp appearance Wobbly, floppy, or limp appearance •Lace-like or mottled skin appearance Lace-like or mottled skin appearance •Blue or gray skin near the mouth or on the hands or feet Blue or gray skin near the mouth or on the hands or feet •Dizziness or lightheadedness Dizziness or lightheadedness •Confusion Confusion •Subdued or less active Subdued or less active •Sleepiness and difficulty waking Sleepiness and difficulty waking •Behavioral changes Behavioral changes •Loss of consciousness Loss of consciousness •Spitting up Spitting up •Back arching Back arching •Inconsolable crying Inconsolable crying •Abdominal pain Abdominal pain •Nausea Nausea •Diarrhea Diarrhea •Vomiting Vomiting Although all anaphylaxis events represent allergic reactions, not all allergic reactions meet the criteria for anaphylaxis, and clinical severity can vary widely. Severity grading systems commonly categorize reactions as mild, moderate, or severe based on symptom patterns and physiological compromise.36 Mild reactions are typically limited to the skin, whereas moderate reactions include symptoms suggestive of evolving systemic involvement. Severe reactions are characterized by cardiovascular and/or respiratory compromise. Importantly, moderate and severe allergic reactions are generally considered indicative of anaphylaxis and warrant prompt epinephrine administration. However, grading systems have important limitations in real-time clinical decision-making, because reactions may progress rapidly and early symptoms can underestimate severity. Consistent with updated anaphylaxis recommendations, a formal diagnosis of anaphylaxis is not a prerequisite for epinephrine use. Epinephrine should be administered whenever there is concern for a potentially serious allergic reaction, particularly when respiratory or circulatory symptoms are present or evolving.2 This approach prioritizes timely treatment over retrospective severity classification and reflects evidence that delays in epinephrine administration are associated with worse outcomes. Although anaphylaxis is a clinical diagnosis, measurement of tryptase levels can be used to support the diagnosis.2 In the 2023 anaphylaxis guidelines, the JTFPP recommends obtaining an acute serum tryptase level during a reaction, with levels above the laboratory-defined normal value suggesting mast cell activation and potential anaphylaxis. For those patients with tryptase levels below this threshold, elevations of at least 20% plus serum tryptase levels 2 ng/mL above baseline obtained before or after a reaction can also be supportive of mast cell activation. Reaction Management Epinephrine is the first-line treatment for anaphylaxis and remains the only medication capable of rapidly reversing the life-threatening respiratory and cardiovascular manifestations of severe allergic reactions.2,11, 12, 13, 14 Through its combined α- and β-adrenergic effects, epinephrine counteracts vasodilation and increased vascular permeability, improves blood pressure and coronary perfusion, relaxes bronchial smooth muscle, and reduces mucosal edema in the upper airway. No other commonly used therapies, including antihistamines or corticosteroids, address these critical pathophysiological processes, and their use should never delay epinephrine administration. Clinical guidelines consistently emphasize that early epinephrine use is associated with improved outcomes, whereas delayed administration is a well-established risk factor for severe morbidity and fatal anaphylaxis.37, 38, 39, 40 Given the unpredictable nature of allergen exposure and reaction severity, guidelines recommend proactive epinephrine prescribing for pediatric patients at risk of anaphylaxis.2,41 Epinephrine prescriptions are recommended for children with an IgE-mediated food allergy due to the risk of accidental exposure and cross-contact, those with insect venom allergy, and individuals with a history of systemic allergic reactions. If a patient with insect venom allergy has completed venom immunotherapy, the decision to continue carrying epinephrine should be individualized in collaboration with an allergy/immunology specialist. Children with comorbid asthma warrant particular attention, because underlying airway disease is associated with an increased risk of severe respiratory compromise during anaphylaxis. Epinephrine is also recommended for patients with mast cell disorders, such as mastocytosis, and those with cold-induced angioedema, who may experience severe or atypical reactions. Effective anaphylaxis preparedness also requires comprehensive counseling of patients, families, and caregivers on epinephrine access and use. Guidelines recommend that children at risk for anaphylaxis carry at least 2 epinephrine devices at all times, given the possibility of an incomplete response to the initial dose, accidental misuse, or recurrence of symptoms, including biphasic reactions. Counseling should emphasize the early recognition of anaphylaxis, clear indications for epinephrine administration, and hands-on training in device use, with periodic reinforcement over time. Families should also receive anticipatory guidance regarding storage and accessibility, including the importance of keeping epinephrine readily available across settings such as home, school, childcare, and extracurricular activities. Historically, families were routinely instructed to activate emergency medical services (EMS) after every use of epinephrine for an allergic reaction, reflecting concerns about symptom recurrence, incomplete response, and biphasic reactions.42 More recent guidance, however, recognizes that a uniform mandate for EMS activation may not be necessary in all circumstances and supports a more individualized approach.43 Decisions regarding EMS activation after epinephrine administration should be guided by the child's clinical response, caregiver comfort and competence, and the availability of additional epinephrine and monitoring resources. Although EMS activation remains appropriate and is strongly advised when symptoms persist or recur after epinephrine use, shared decision-making may be reasonable in carefully selected lower-risk situations in which symptoms resolve promptly and completely after the initial epinephrine dose. Home or community observation is not appropriate if the caregiver is not confident in their ability to monitor the patient or if they do not have access to an additional epinephrine dose. Key considerations that may favor home or community management vs EMS activation following epinephrine use are summarized in Table III. Patients and families should be informed that biphasic reactions are more likely with severe initial symptoms but are uncommon overall, especially when epinephrine is administered promptly (<1% of cases), and generally less severe than the initial reaction.44,45 Table IIIConsiderations favoring home or community management vs EMS activation after epinephrine use43,46Favors home or community management (less risk)Favors EMS activation (more risk)•Signs and symptoms resolved quickly and completely with first epinephrine dose•Engagement of the caregiver in shared decision-making•Immediate access to one or more additional epinephrine devices•Ability to monitor and administer epinephrine if needed•Clear understanding of signs/symptoms warranting further care•Noncutaneous signs and symptoms persisting or worsening after first epinephrine dose•Caregiver not comfortable with home observation•No access to additional epinephrine devices•Inability to monitor and administer epinephrine if needed•History of near-fatal anaphylaxis Considerations favoring home or community management vs EMS activation after epinephrine use43,46 •Signs and symptoms resolved quickly and completely with first epinephrine dose Signs and symptoms resolved quickly and completely with first epinephrine dose •Engagement of the caregiver in shared decision-making Engagement of the caregiver in shared decision-making •Immediate access to one or more additional epinephrine devices Immediate access to one or more additional epinephrine devices •Ability to monitor and administer epinephrine if needed Ability to monitor and administer epinephrine if needed •Clear understanding of signs/symptoms warranting further care Clear understanding of signs/symptoms warranting further care •Noncutaneous signs and symptoms persisting or worsening after first epinephrine dose Noncutaneous signs and symptoms persisting or worsening after first epinephrine dose •Caregiver not comfortable with home observation Caregiver not comfortable with home observation •No access to additional epinephrine devices No access to additional epinephrine devices •Inability to monitor and administer epinephrine if needed Inability to monitor and administer epinephrine if needed •History of near-fatal anaphylaxis History of near-fatal anaphylaxis Antihistamines play a limited, supportive role in anaphylaxis management and should be clearly distinguished from first-line therapy. Because of their relatively slow onset of action and inability to reverse airway obstruction, hypotension, or shock, antihistamines are considered second-line agents and must never be used in place of epinephrine.11 After epinephrine has been given and symptoms are improving, second-generation antihistamines (eg, cetirizine, loratadine, levocetirizine, fexofenadine, and desloratadine) may be considered for the relief of persistent cutaneous manifestations such as urticaria or pruritus. Sedating antihistamines, including diphenhydramine and hydroxyzine, are generally discouraged in pediatric patients, because sedation may complicate monitoring for progression or recurrence of anaphylaxis.2 Written anaphylaxis action plans are a cornerstone of pediatric preparedness and translate clinical guidance into clear, actionable steps for families, schools, and other caregivers. Effective action plans outline how to recognize the early signs and symptoms of anaphylaxis, when and how to administer epinephrine, how to monitor after treatment, and when to activate EMS.47 Plans should also include practical instructions for medication use and emphasize that epinephrine should be administered promptly when indicated. Standardized, age-appropriate templates are widely available, including a recently updated action plan developed by North American experts and patients that includes the watchful waiting approach to EMS activation.48 Reviewing and updating action plans during routine pediatric visits ensures that management changes are documented, reinforces caregiver confidence, supports coordinated care across home and school environments, and helps to ensure timely, appropriate responses during allergic emergencies. Epinephrine Device Considerations Epinephrine has been used to treat severe allergic reactions for more than a century, but the introduction of epinephrine autoinjectors (EAIs) fundamentally changed anaphylaxis care by enabling rapid, reliable treatment outside of medical facilities. Since the US FDA approval of the first EAI in 1987, EAIs have served as the standard of care for community-based management of anaphylaxis, allowing patients, families, and caregivers to administer life-saving therapy promptly at the point of reaction. Over subsequent decades, additional injectable epinephrine products have been approved to improve accessibility and usability, including different device designs and generic formulations (Figure and Table 4). Notably, none of these approvals required head-to-head clinical efficacy trials, reflecting the longstanding assumption that intramuscular epinephrine delivered at recommended doses would have comparable pharmacokinetic and clinical effects across devices. Major milestones in epinephrine delivery device development. Table IVApproved epinephrine devicesCharacteristicsEpiPen/EpiPen Jr (Mylan)Epinephrine injection (Teva Pharmaceuticals)Epinephrine injection (Amneal Pharmaceuticals)Auvi-Q (Kaleo)Symjepi (Adamis)neffy (ARS Pharma)FormAutoinjectorAutoinjectorAutoinjectorAutoinjectorPrefilled syringeIntranasal spray Generic availableYesGeneric equivalent of EpiPen/EpiPen JrAuthorized generic of AdrenaclickNoNoNoDosage and administration RouteIMIMIMIMIM or SCIntranasal Weight-based dosing33-66 lb: 0.15 mg>66 lb: 0.3 mg33-66 lb: 0.15 mg>66 lb: 0.3 mg33-66 lb: 0.15 mg>66 lb: 0.3 mg16.5-33 lb: 0.10 mg33-66 lb: 0.15 mg>66 lb: 0.3 mg33-66 lb: 0.15 mg>66 lb: 0.3 mg33-66 lb: 1 mg>66 lb: 2 mg Administration stepsRemove from carrying caseRemove blue end capPlace orange tip against anterolateral thighPress down firmly and holdTwist off the green or yellow end capRemove blue end capPlace orange tip against anterolateral thighSwing and push firmly into thigh until it clicksRemove from carrying caseRemove both end capsPlace red tip against anterolateral thighPress hard and firmly holdPull up from casingPull red safety guard firmly to removePlace black end against anterolateral thighPush firmly until click and hiss then holdRemove capHold by finger gripsSlowly insert needle into anterolateral thighPush plunger until it clicks then holdRemove from packagingHold with thumb on the plunger and fingers next to nozzleInsert nozzle straight into nostrilPress plunger until it snaps and sprays Hold time3 seconds3 seconds10 seconds2 seconds2 secondsN/A Second doseAdminister in same or opposite thighAdminister in same or opposite thighAdminister in same or opposite thighAdminister in same or opposite thighAdminister in same or opposite thighAdminister in same nostrilStorage/carriage Storage temperature68-77 °F68-77 °F68-77 °F68-77 °F68-77 °F68-77 °F Temperature excursionsUp to 86 °FUp to 86 °FUp to 86 °FUp to 86 °F59-86 °FUp to 122 °F Light protectionYesYesYesYesYesNo Approximate size∼6 inches long∼6 inches long∼6 inches long∼3.5 inches tall and ∼2 inches wide∼4 inches tall and ∼2 inches wide∼2 inches tall and ∼2 inches wide Shelf life12-18 months12-18 months12-18 months12-18 months12-18 months24-30 months Special featuresNeedle covered after injectionNeedle covered after injectionIf needle is sticking out after injection, full dose was injectedNeedle covered after injectionVoice promptDose window confirming full doseNeedle freeIM, intramuscular; SC, subcutaneous. Approved epinephrine devices Remove from carrying case Remove from carrying case Remove blue end cap Remove blue end cap Place orange tip against anterolateral thigh Place orange tip against anterolateral thigh Press down firmly and hold Press down firmly and hold Twist off the green or yellow end cap Twist off the green or yellow end cap Remove blue end cap Remove blue end cap Place orange tip against anterolateral thigh Place orange tip against anterolateral thigh Swing and push firmly into thigh until it clicks Swing and push firmly into thigh until it clicks Remove from carrying case Remove from carrying case Remove both end caps Remove both end caps Place red tip against anterolateral thigh Place red tip against anterolateral thigh Press hard and firmly hold Press hard and firmly hold Pull up from casing Pull up from casing Pull red safety guard firmly to remove Pull red safety guard firmly to remove Place black end against anterolateral thigh Place black end against anterolateral thigh Push firmly until click and hiss then hold Push firmly until click and hiss then hold Remove cap Remove cap Hold by finger grips Hold by finger grips Slowly insert needle into anterolateral thigh Slowly insert needle into anterolateral thigh Push plunger until it clicks then hold Push plunger until it clicks then hold Remove from packaging Remove from packaging Hold with thumb on the plunger and fingers next to nozzle Hold with thumb on the plunger and fingers next to nozzle Insert nozzle straight into nostril Insert nozzle straight into nostril Press plunger until it snaps and sprays Press plunger until it snaps and sprays Needle covered after injection Needle covered after injection Needle covered after injection Needle covered after injection If needle is sticking out after injection, full dose was injected If needle is sticking out after injection, full dose was injected Needle covered after injection Needle covered after injection Voice prompt Voice prompt Dose window confirming full dose Dose window confirming full dose Needle free Needle free IM, intramuscular; SC, subcutaneous. Although injectable epinephrine devices made it possible for patients and caregivers to treat anaphylaxis in community settings, such as homes, schools, and childcare facilities, real-world use of epinephrine remains suboptimal. Population-based studies consistently show low rates of epinephrine prescribing for children at risk of anaphylaxis. Even among those with prescriptions, rates of prescription fills, consistent carriage, and timely use during reactions are suboptimal.49,50 Instead, oral antihistamines are frequently used as initial treatment despite their inability to address respiratory or cardiovascular compromise.51 This underuse of epinephrine has important clinical consequences; delayed or absent administration has been associated with an increased risk of biphasic reactions, emergency department utilization, hospitalization, and fatal anaphylaxis.37, 38, 39, 40 Multiple barriers contribute to these gaps in use, including resistance to seeking emergency care after epinephrine administration, fear of needles among patients and caregivers, risks of needle-related injuries in smaller children, concerns regarding epinephrine adverse effects, high out-of-pocket costs, and challenges related to device size and portability.37,49,51, 52, 53, 54 Together, these limitations highlight persistent unmet needs in community-based anaphylaxis management and underscore the importance of equipping pediatricians with epinephrine delivery options and counseling strategies that may help to reduce barriers to timely treatment in real-world settings. Needle-Free Epinephrine The approval of neffy in 2024 marked the first needle-free epinephrine option for the emergency treatment of allergic reactions, including anaphylaxis. neffy is a saline-based intranasal formulation that combines epinephrine with 2 components commonly used in other FDA-approved nasal sprays: an absorption enhancer (dodecyl maltoside [Intravail]) and a unit-dose spray delivery system.55 Similar to EAIs, neffy was not evaluated in randomized controlled trials for efficacy because of ethical and practical limitations. Instead, approval was based on a comprehensive development program comprising multiple pharmacokinetic and pharmacodynamic studies.55, 56, 57, 58 These trials were designed to reflect potential real-world conditions, including self-administration, the presence of allergic or infectious rhinitis, and models of severe hypotension. neffy pharmacologic data are now supported by postapproval efficacy data from a phase 3 clinical trial and effectiveness data from a large real-world cohort.59,60 In pediatric patients, the clinical efficacy of intranasal epinephrine was evaluated in a phase 3 study that included patients with oral food challenge (OFC)-induced anaphylaxis.59 In this open-label study, 15 children aged 6-17 years with food allergy received weight-based intranasal epinephrine for grade 2 or higher gastrointestinal, respiratory, or cardiovascular symptoms during OFCs. Grade 2 symptoms are considered moderate in severity and include generalized urticaria, throat pain, chest tightness, or mild hypotension. All patients responded to the initial dose, with no second dose required within 15 minutes of administration and a median time to grade 2 symptom resolution of 16 minutes. One patient experienced a biphasic reaction approximately 2 hours and 45 minutes after the initial dose and was treated with a second epinephrine dose administered by intramuscular injection. Mild to moderate adverse events were reported in 7 patients, most commonly tremor and transient erythema of the nasal mucosa, with no serious adverse events observed. Additional data from real-world use further inform intranasal epinephrine administration outside controlled trial settings.60 In a large real-world experience program survey of healthcare providers, intranasal epinephrine was administered to 680 patients for allergic reactions occurring during OFCs or allergen immunotherapy. A single intranasal dose was effective in 88.7% of patients, and 11.3% required a second epinephrine dose, consistent with published rates after food-induced anaphylaxis.60 Both clinicians and patients rated ease of use highly, suggesting favorable usability in real-world clinical environments. Together, these postapproval data complement pharmacologic studies and support intranasal epinephrine as an effective needle-free alternative for the emergency treatment of allergic reactions, including anaphylaxis, in pediatric populations. However, longer-term real-world experience and clinical outcome data remain more limited than for established injectable epinephrine devices, and continued postmarketing surveillance will be important to further define the use of intranasal epinephrine across diverse pediatric anaphylaxis scenarios. In addition to currently approved intranasal epinephrine, other needle-free epinephrine delivery approaches are under investigation, including alternative intranasal formulations and a sublingual epinephrine option.41,61 Early-phase studies evaluating these modalities have demonstrated pharmacokinetic and pharmacodynamic profiles that approximate those observed with injectable epinephrine, including rapid systemic absorption and physiological effects. Although these products remain investigational and are not yet approved for clinical use, continued development may increase the number of needle-free epinephrine options in the future. The expanding availability of needle-free epinephrine provides pediatricians with additional flexibility to address persistent barriers to anaphylaxis preparedness. Candidates for prescribing intranasal epinephrine include children and/or caregivers who demonstrate fear of needles or needle avoidance; those who inconsistently fill, carry, or use injectable epinephrine; and families who report or anticipate difficulties with device activation in real-world settings (eg, use by childcare providers or school staff). For pediatricians, identifying barriers to injectable epinephrine during routine visits or after allergic reactions creates an opportunity to tailor epinephrine prescribing to better align with patient and caregiver preferences and behaviors. Conclusions Anaphylaxis is a medical emergency in which outcomes hinge on rapid recognition and timely treatment. Epinephrine is a highly efficacious and well-established therapy with a long record of safety. It remains the unequivocal first-line treatment for anaphylaxis across pediatric age groups. Despite this, avoidance or delayed use of epinephrine continue to occur in real-world settings, underscoring the ongoing need for improved education of patients and caregivers on recognizing early signs of anaphylaxis and administering epinephrine without hesitation. Recent advances in epinephrine delivery, including the availability of needle-free intranasal epinephrine, offer the same life-saving medication in more convenient formats that may help to address longstanding barriers to carriage and use. By pairing clear education, individualized emergency preparedness planning, and thoughtful selection of epinephrine delivery options, pediatricians can play a pivotal role in closing the gaps between evidence-based recommendations and real-world practice, ultimately improving safety and outcomes for children at risk of anaphylaxis. CRediT authorship contribution statement Jonathan M. Spergel: Writing – review & editing, Writing – original draft, Resources, Methodology, Formal analysis, Conceptualization. Anna Nowak-Wegrzyn: Writing – review & editing, Writing – original draft, Resources, Formal analysis, Conceptualization. Joel Brooks: Writing – review & editing, Writing – original draft, Resources, Formal analysis, Conceptualization. Suzanne Kochis: Writing – review & editing, Writing – original draft, Resources, Formal analysis, Conceptualization. Declaration of Competing Interest Medical writing support for this article was provided by ARS Pharmaceuticals Operations, Inc. J.M.S. reports research support from Novartis, AstraZeneca, Regeneron, ARS Pharmaceuticals, and Sanofi. He reports serving as a consultant and/or advisor for ARS Pharmaceuticals, Regeneron, and Sanofi, and royalties from Uptodate. A.N.-W. reports contracting by DBV Technologies, ALK, and Siolta Therapeutics. She reports serving as an advisor for Nestle, Danone, and Genentech; and she reports serving as a speaker for Nestle. S.K. reports salary supported by partnership between CNH and NIAID/Leidos for fellowship site director position and salary supported by industry-sponsored clinical trials as a co-investigator, including ARS EPI R01, DBV, and RAPT. She receives no direct funds. References